Literature DB >> 10199774

Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency.

F Borson-Chazot1, A Serusclat, Y Kalfallah, X Ducottet, G Sassolas, S Bernard, F Labrousse, J Pastene, A Sassolas, Y Roux, F Berthezène.   

Abstract

An increased carotid arterial intima-media thickness (IMT) has been reported in hypopituitary adults untreated for GH deficiency. In the present study, the effect of GH replacement on IMT and cardiovascular risk factors was prospectively investigated, in GH deficiency patients treated at a mean dose of 1 UI/day during 1 yr (n = 22) and 2 yr (n = 11). The IMT measurements were performed by the same experienced physician, and the coefficient of variation (calculated in two control groups) was below 6.5%. IMT at baseline was related to conventional risk factors. After 1 yr GH treatment, IMT decreased from 0.78 +/- 0.03 mm to 0.70 +/- 0.03 mm (P < 0.001). The decrement was observed in 21 of 22 patients. After 2 yr GH treatment, IMT had stabilized at 0.70 +/- 0.04 mm and remained significantly different from baseline values (P < 0.003). GH treatment resulted in a moderate decrease in waist circumference and body fat mass and an increase in VO2 max. Conventional cardiovascular risk factors were unmodified except for a transient 10% decrease in low-density lipoprotein cholesterol at 6 months. The contrast between the limited metabolic effect of treatment and the importance and precocity of the changes in IMT suggests that the decrease in IMT was not exclusively attributable to a reversal in the atherosclerotic process. A direct parietal effect of GH replacement on the arterial wall might also be involved. The consequences, in terms of cardiovascular risk, should be established by randomized prospective trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199774     DOI: 10.1210/jcem.84.4.5595

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Evaluation of function and structure of arterial wall in girls and young women with Turner syndrome.

Authors:  G Radetti; L Mazzanti; C Di Somma; M Salerno; E Gottardi; D Capalbo; F Tamburrino; A Colao
Journal:  J Endocrinol Invest       Date:  2015-04-02       Impact factor: 4.256

3.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 4.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

Review 5.  Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Yingxuan Wang; Guixia Wang
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

6.  Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age.

Authors:  A Colao; S Spiezia; C Di Somma; R Pivonello; P Marzullo; F Rota; T Musella; R S Auriemma; M C De Martino; G Lombardi
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

7.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

8.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

9.  Hypothesis: Neuroendocrine Mechanisms (Hypothalamus-Growth Hormone-STAT5 Axis) Contribute to Sex Bias in Pulmonary Hypertension.

Authors:  Pravin B Sehgal; Yang-Ming Yang; Edmund J Miller
Journal:  Mol Med       Date:  2015-07-30       Impact factor: 6.354

10.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.